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Background: Esomeprazole is the most effective treatment for acid-related disorders and is
widely used with enteric coating due to rapid degradation in the acidic environment.
However, the enteric-coated formulation delays absorption and onset of action. To overcome
this limitation, an immediate-release formulation containing esomeprazole 20 mg and
sodium bicarbonate 800 mg (IR-ESO) was developed.
Purpose: To evaluate the safety, pharmacokinetics (PK), and pharmacodynamics of IR-ESO
compared to those of esomeprazole 20 mg (ESO).
Methods: A randomized, open-label, multiple-dose, two-treatment, two-sequence crossover
study was conducted in 40 healthy male subjects. Subjects received either IR-ESO or ESO
for 7 days. After single and multiple dosing, blood samples were collected for PK analysis,
and intragastric pH was assessed by 24-hr pH monitoring.
Results: Plasma esomeprazole exposure of IR-ESO was similar to that of ESO after single
and multiple dosing. Time to peak concentration of IR-ESO (0.50–0.75 hr) was shorter than
that of ESO (1.25–1.50 hr). Percentage changes in 24-hr integrated gastric acidity from
baseline for IR-ESO were similar to those for ESO. In addition, mean time to maintain
gastric pH >4 for 24 hr was similar for both drugs (IR-ESO 55.5–69.9% vs ESO 56.8–
70.2%). Evaluation of time to ﬁrst reach pH 4 after dosing indicated that IR-ESO showed a
faster onset than ESO. All subjects found the drug tolerable, and there were no signiﬁcant
differences in adverse events between two drugs.
Conclusion: This study showed that IR-ESO produced a rapid, safe and sustained gastric
acid suppression (ClinicalTrials.gov: NCT03211143).
Keywords: sodium bicarbonate, immediate-release esomeprazole, esomeprazole, 24-hr pH
monitoring
Introduction
Gastro-esophageal reﬂux disease (GERD) is the most common acid-related disorder, and
its typical symptoms include heartburn and/or regurgitation.1 The goal of treatment for
GERD is to achieve symptomatic relief.2 The severity and frequency of these symptoms
signiﬁcantly correlate with the degree of esophageal exposure to acid and the pH of the
reﬂuxate.3 It is necessary to suppress gastric acid for relieving the symptoms.
Proton pump inhibitors (PPIs) are widely used for the treatment of GERD, and
they act by suppressing gastric acid secretion and raising intragastric pH.4
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Esomeprazole is one of the most frequently prescribed PPI
and provides more rapid and effective relief than other
PPIs.5 However, esomeprazole is prone to degradation by
gastric acid in the stomach.6,7 To overcome this shortcom-
ing and protect it from rapid degradation, esomeprazole
was improved via enteric coating.8,9 The enteric-coated
formulation of esomeprazole enhanced the stability of
active ingredients in the stomach; however, it also led to
delayed absorption and onset of action.8,9
Some studies have indicated that a single dose might not
be sufﬁcient to achieve maximum effectiveness due to
delayed absorption of enteric-coated esomeprazole.10,11
Esomeprazole with enteric coating showed therapeutic efﬁ-
cacy of approximately 68.3% after 8 weeks of treatment;
however, the efﬁcacy was about 45.3% after single dose.12
Despite remarkable effects with respect to the management
of GERD, lack of an immediate response might contribute
to patient dissatisfaction with treatment and could lead to
unnecessary increases in dosage or inappropriate switching
to alternate members of this class.10
The sodium bicarbonate is a chemical compound which
can be used as an antacid. It raises the pH of the stomach
and creates a chemical umbrella that protects the esomepra-
zole and allows it to pass safely to the duodenum where it is
absorbed.13 An immediate-release (IR) formulation con-
taining esomeprazole 20 mg and sodium bicarbonate 800
mg (IR-ESO; Chong Kun Dang Pharmaceutical Corp.,
Seoul, Korea) was developed to mitigate the delayed onset
of action. This study was designed to compare the pharma-
cokinetics (PK) and pharmacodynamics (PD) of IR-ESO
with those of an enteric-coated formulation of
esomeprazole.
Materials and methods
Ethics
The protocol was approved by the Institutional Review
Board (IRB) of Severance Hospital (Seoul, South Korea,
IRB number 4-2017-0310) and the Ministry of Food and
Drug Safety. It is also registered at the ClinicalTrials.gov
(Identiﬁer: NCT03211143). This study was carried out in
accordance with the Declaration of Helsinki and the Korean
Good Clinical Practice (KGCP). All subjects provided writ-
ten informed consent before enrolment in this study.
Subjects
Healthy male subjects aged 19–50 years with body mass
index (BMI) between 18.5 and 25.0 kg/m2 were
considered for participation in the study. The volunteers
were determined as healthy based on medical history,
physical examinations, 12-lead electrocardiography
(ECG), and laboratory tests such as hematology, serum
chemistry, urinalysis, and serology (negative for hepatitis
B surface antigen, anti-hepatitis C virus antibody, human
immunodeﬁciency virus serology, and syphilis reagin test).
In addition, subjects who met the following criteria were
excluded: current smoker, medical history of disease that
might inﬂuence the PK or PD evaluation in this study,
history of clinically signiﬁcant hypersensitivity reaction to
drugs, or positive results in urine drug screening. During
the study period, all the subjects were prohibited to take
any drugs, herbals, or over-the-counter drugs that could
affect PK or PD evaluation. Additionally, subjects were
not allowed to smoke or consume alcohol, caffeine, any
beverage, or food except the ones provided.
Study design
This was a randomized, open-label, multiple-dose, two-
treatment, and two-sequence crossover study design. The
two treatments administered were as follows: a ﬁxed dose
combination tablet consisting of 20 mg of esomeprazole
and 800 mg of sodium bicarbonate once daily for 7 days
(test treatment, T), and a tablet of esomeprazole 20 mg
once daily for 7 days (reference treatment, R). Forty sub-
jects were randomly assigned to one of the two sequence
groups (T-R or R-T) in 1:1 ratio. Each treatment period
was separated by a 7-day washout period.
All subjects were hospitalized in the clinical trials center
during each treatment period (from Day −2 to Day 8). They
underwent 24-hr gastric pH monitoring at baseline, after
single administration and after multiple administrations of
test or reference treatment in each period. The pH measure-
ment and recording started 30 mins before study drug
administration (at approximately 08:00) and were continu-
ously conducted for 24 hrs. During the 24-hr intragastric pH
monitoring, all subjects were required to maintain similar
posture to minimize its effect on gastric pH. They were
required to lie down on the bed during nighttime (23:00 to
07:00) and maintain upright posture with at least 45 degrees
during daytime (07:00 to 23:00).
In addition, all the participants received each treatment
with 150 mL water under fasting conditions at approxi-
mately 08:00 on Day 1 through 7 of each period. During
every dose administration and 24-hr intragastric pH mon-
itoring, they ate breakfast at approximately 09:00 for 20
mins and were served lunch and dinner at 13:00 and 18:00,
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respectively. All meals were nutritionally equivalent (700–
800 kcal, containing 5–25% fat content) and were pro-
vided at the same time scheduled throughout the study
period.
On Days 1 and 7 during each period, blood samples
were collected for PK analysis in sodium heparin tubes
prior to dose administration, and after 0.17 (=10 mins),
0.33 (=20 mins), 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5,
6, 8, 10, and 12 hrs on Days 1 and 7 during each period.
The collected blood samples were centrifuged at 3,000
rpm at 4°C for 10 mins and stored below −70°C until
analysis.
Plasma esomeprazole assay
The plasma samples for esomeprazole concentration mea-
surement were analyzed using a high-performance liquid
chromatography assay, coupled with triple quadrupole
mass spectrometer (API 4000, AB SCIEX, USA)
equipped with electrospray ionization in positive ion
mode. A 50 μL plasma sample was prepared by protein
precipitation by mixing with 10 μL of esomeprazole-d3
(500 ng/mL) and 600 μL of acetonitrile. After centrifuga-
tion at 13,500 rpm for 10 mins, 2 μL supernatant was
injected into the column (Hypersil GOLD, 150*2.1 mm,
5 μm) in the mobile phase, which consisted of 10 mM
ammonium formate:acetonitrile with 0.1% formic acid
(50:50, v/v). The lower limit of quantiﬁcation was 1 ng/
mL, and precision and accuracy were less than 15%
coefﬁcient of variation. The calibration curves had ade-
quate linearity as r >0.9959 in the ranges of 1 to 3,000
ng/mL of sample concentration.
Pharmacokinetic analysis
The PK parameters for esomeprazole were calculated by
non-compartmental analysis using Phoenix WinNonlin
version 7.0 (Certara, Princeton, NJ, USA). The maximum
plasma concentration (Cmax) and time to reach maximum
plasma concentration (Tmax) were determined directly
from the observed data. The area under the plasma con-
centration–time curve (AUC) within a dose interval (τ)
(AUCτ) and AUC to the last measurable time (AUClast)
was calculated using the linear trapezoidal rule. The term-
inal elimination rate constant (ke) was estimated by log-
linear regression analysis. The elimination half-life (t1⁄2)
and the apparent plasma clearance (CL/F) were calculated
from the equation, t1⁄2=ln(2)/ke and CL/F=dose/AUC,
respectively. AUC from 0 to inﬁnity (AUCinf) was
obtained by summation of AUClast and Clast/ke. The
apparent volume of distribution (Vd/F) was calculated
from the equation, Vd/F=Dose/(ke∙AUCinf).
Intragastric pH monitoring
Intragastric pH monitoring was performed using an impe-
dance-pH recorder (Ohmega R, Enschede, Netherlands).
Before each 24-hr intragastric pH monitoring, the pH
catheter and catheter-based ambulatory pH monitoring
system were calibrated using standard buffer solutions
(pH 4.0 and 7.0). On Day 1, a pH catheter was inserted
into the stomach, and the point (cm) where the pH dropped
abruptly to <2.5 for each subject was recorded. The cathe-
ter was inserted at the same point for each subject during
all 24-hr intragastric pH monitoring. The measurements
were taken every second for 24 hrs.
Pharmacodynamic analysis
The primary PD parameters were percentage decrease in
integrated gastric acidity from baseline over a 24-hr inter-
val (%IA24hr) after multiple administrations (Day 7).
Additionally, PD parameters included %IA24hr after single
administration (Day 1), percentage of time with gastric pH
>4 for 24-hr interval, and mean gastric acid concentration
after single and multiple administrations. Integrated gastric
acidity was calculated using the following method.14
Baseline integrated gastric acidity was calculated as the
mean of baseline intragastric pH measured between two
periods.
● Acid concentration (mmol/L) =1,000×10−pH
● Acidity (mmol∙hr/L) = (acid in mmol/L at time “t” +
acid in mmol/L at time “t−1”)/2×(t-t−1)
● Acidity values were summed cumulatively per sec-
ond. Integrated acidity is expressed as mmol/L×time,
ie, mmol∙hr/L
● Integrated gastric acidity was analyzed for each hour
of the recording
%IA24hr after single or multiple administrations was
calculated using the following method.
%IA24hr after single or multiple administrations (%) =
[(Baseline – Day 1 or Day 7)/Baseline] ×100
Safety evaluation
Adverse events (AE) were monitored throughout the study.
Safety evaluation was performed as follows: physical
examination, monitoring of vital signs, 12-lead ECG, and
laboratory tests including hematology, serum chemistry,
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and urinalysis. All AEs were collected using MedDRA®
(Ver. 19.0) dictionary.
Statistical analyses
The PK and PD data were analyzed to compare the treat-
ment groups. The primary PK parameter (AUCτ) and PD
parameter (%IA24hr after multiple administrations) were
log-transformed and analyzed by analysis of variance
using a mixed-effects model. To compare the primary PK
and PD parameters, point estimates and 90% conﬁdence
intervals (CI) for the geometric mean ratios (T/R) were
also presented. Demographic characteristics were analyzed
using the independent two sample t-test and chi-square test
for comparison of two sequence groups (T-R and R-T).
Safety data were presented using descriptive statistics. All
statistical analyses were conducted using SAS statistical
software version 9.3 (SAS Institute Inc. Cary, NC, USA)
and Phoenix WinNonlin version 7.0 (Certara, Princeton,
NJ, USA).
Results
Study participants
A total of 40 subjects were enrolled in this study and
received at least one dose of study drugs. One subject
withdrew from the study after completing the schedule of
period 1 and was not included in the PK and PD analysis
set. Two subjects completed all schedules in this study but
were excluded from the PD analysis set because the miss-
ing rate for the pH monitoring measurements was more
than 5%. All the subjects were men, and there were no
signiﬁcant differences in demographics between the two
sequence groups (T–R and R–T) (Table 1).
Pharmacokinetics
The details of PK parameters of esomeprazole in each
group are summarized in Table 2. After single or multiple
administrations, the plasma concentration of esomeprazole
in the test group showed a rapid increase, while those in
the reference group increased gradually (Figure 1). Median
Tmax of esomeprazole for the test group was shorter than
that for the reference group upon both single and multiple
administrations. The Tmax was 0.50 hr and 0.75 hr for the
test group after single and multiple administrations,
respectively, while the values were 1.50 and 1.25 hr for
the reference group in each administration.
The Cmax of the test group demonstrated an approxi-
mately 1.53-fold and 1.44-fold increase as compared to
that of the reference group after single and multiple
administrations, respectively. However, the AUC of
esomeprazole after single or multiple administrations was
similar between the two formulations, and the t1/2, CL/F,
and Vd/F of esomeprazole in the test group were similar to
those of the reference group.
Pharmacodynamics
The intragastric pH over 24 hrs (median pH per 15 mins)
at baseline, after single and multiple administrations is
illustrated in Figure 2. Meal times and time of supine
position are also indicated in Figure 2. The proﬁles of
intragastric pH over 24 hrs for both single and multiple
administrations were generally similar between the two
treatment groups. The intragastric pH within 2 hrs (median
pH per 1 min) after single and multiple administrations is
shown in Figure 3. The ﬁrst time to reach pH >4 after
single and multiple administrations was about 55 and 27
mins in the test group, and 67 and 46 mins in the reference
group, respectively.
The mean percentage times observed for gastric pH >4
at baseline, on Day 1 and Day 7 are presented in Figure 4.
The mean (SD) percentage time for gastric pH >4 on Day
1 was 56.8% (22.8%) for test group compared with 55.5%
(21.6%) for reference group (P=0.806). The mean (SD)
Table 1 Demographic characteristics of subjects
Total (n=40) Sequence Aa (n=20) Sequence Bb (n=20) P-value*
Male, n (%) 40 (100.0%) 20 (100.0%) 20 (100.0%)
Age (years) 28.1±6.6 26.7±5.2 29.5±7.7 0.194
Weight (kg) 68.3±5.4 66.7±5.6 69.8±4.9 0.069
Height (cm) 174.0±5.4 173.1±5.2 174.9±5.5 0.295
BMI (kg/m2) 22.5±1.4 22.2±1.5 22.8±1.2 0.197
Notes: Data are presented as mean±SD or as n (%) of subjects. aSequence A: esomeprazole 20 mg/sodium bicarbonate 800 mg once daily for 7 days (test treatment) →
esomeprazole 20 mg once daily for 7 days (reference treatment). bSequence B: esomeprazole 20 mg once daily for 7 days (reference treatment) → esomeprazole 20 mg/
sodium bicarbonate 800 mg once daily for 7 days (test treatment). *P-values were calculated by using an independent t-test.
Abbreviations: BMI, body mass index; SD, standard deviation.
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percentage time for gastric pH >4 on Day 7 was 69.9%
(15.9%) for the test group compared to 70.2% (16.6%) for
reference group (P=0.951). The time to maintain pH >4
was similar between the two groups on both Day 1 and
Day 7.
The 24-hr integrated intragastric acidity and %IA24hr
after single and multiple administrations are summarized
in Table 3. The 24-hr integrated intragastric acidity
decreased signiﬁcantly from the baseline after administra-
tion of the study drugs. Mean %IA24hr in test group as
compared to the baseline was similar to those of reference
group after single or multiple administrations. The point
estimates (with 90% CI) of the geometric mean ratios for
%IA24hr after single and multiple administrations were
1.01 (0.93–1.09) and 1.00 (0.95–1.04), respectively.
Safety
There were no serious AEs observed during the study.
Adverse drug reactions (ADR) occurred in seven subjects
(10 cases) in the test group and two subjects (3 cases) in
the reference group. The most common AEs were dyspep-
sia, pyrexia, and headache. All the AEs were mild, and all
subjects recovered without any complications. During the
study, there was no statistically signiﬁcant difference in the
frequency of ADRs between the test group and reference
group (P=0.106). Furthermore, there were no clinically
signiﬁcant changes in physical examination, vital signs,
ECG, or clinical laboratory results.
Discussion
This randomized, open-label, multiple-dose study compared
the PK and PD of esomeprazole between IR-ESO and a tablet
of enteric-coated esomeprazole 20 mg in healthy male sub-
jects. In this study, the two drugs showed similar PK and PD
proﬁles, indicating that the two drugs have a similar extent of
absorption and acid inhibitory effects.
Esomeprazole, the S-isomer of omeprazole, is widely
used for the treatment of acid-related disorders.7 In pre-
vious studies, esomeprazole showed more efﬁcacy in
maintaining the intragastric pH and exhibited greater inhi-
bition of gastric acid secretion compared to omeprazole.15
To ensure its stability in the stomach, like other PPIs,
esomeprazole was also developed to a delayed-release
enteric coating formulation.16–18 However, the enteric-
coated esomeprazole delayed the onset time of therapeutic
effect due to delayed absorption.19 Therefore, IR-ESO was
developed to overcome this limitation of delayed onset, to
facilitate a rapid effect.
Table 2 PK parameters and comparison of esomeprazole after single and multiple administrations
PK Parameters R (n=39) T (n=39) GMR (90% CI)
T/R
Single administration
Cmax (ng/mL) 822.85±409.71 1184.51±494.32 1.53 (1.29–1.83)
AUClast (hr·ng/mL) 1597.69±961.23 1481.24±742.86 0.99 (0.90–1.09)
Tmax (hr) 1.50 (1.00, 4.00) 0.50 (0.33, 1.25) –
t1/2 (hr) 1.20±0.35 1.19±0.34 –
CL/F (L/hr) 18.53±15.50 16.79±7.98 –
Vd/F (L) 27.33±15.50 26.01±8.76 –
Multiple administration
Cmax (ng/mL) 1164.79±451.15 1562.93±410.30 1.44 (1.28–1.60)
AUCtau, (hr·ng/mL) 2838.20±1193.27 3017.60±1188.50 1.09 (1.03–1.14)
AUClast (hr·ng/mL) 2802.83±1151.05 2991.03±1155.03 1.09 (1.04–1.15)
AUCinf (hr·ng/mL) 2838.70±1194.12 3017.89±1188.99 –
Tmax (hr) 1.25 (0.75, 5.00) 0.75 (0.33, 1.50) –
t1/2 (hr) 1.49±0.39 1.48±0.34 –
CL/F (L/hr) 8.68±4.92 7.71±3.16 –
Vd/F (L) 16.55±4.46 15.21±3.29 –
Notes: Data are presented as mean±SD, except for Tmax (presented as median (min, max)). R, esomeprazole 20 mg once daily for 7 days; T, esomeprazole 20 mg/sodium
bicarbonate 800 mg once daily for 7 days.
Abbreviations: SD, standard deviation; CI, conﬁdence interval; GMR, geometric least squares mean ratio; Cmax, maximum plasma concentration; AUClast, area under the
plasma concentration versus time curve (AUC) from time 0 to the last measurable concentration; Tmax, time of maximum drug concentration; t1/2, elimination half-life; CL/F,
apparent total clearance; Vd/F, apparent volume of distribution; AUCtau, AUC within a dosage interval (τ) at steady state; AUCinf, AUC from time 0 to inﬁnity.
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The ﬁrst time to reach pH >4 after single and multiple
administrations was faster in the IR-ESO group than in the
enteric-coated esomeprazole group. The pH proﬁling
within 2 hrs after each drug administration showed that
pH increased abruptly after IR-ESO administration, but
after the administration of enteric-coated esomeprazole,
the pH was maintained around 2, and then increased
after breakfast. This rapid pH increase by IR-ESO might
be due to the immediate release of esomeprazole. In addi-
tion, sodium bicarbonate acts as a buffer to protect esome-
prazole from gastric acid degradation, and it stimulates the
temporary release of gastrin.20 The increase in gastrin
levels allows parietal cells to absorb esomeprazole before
degradation by the gastric acid.10 In addition, sodium
bicarbonate acts as an antacid and rapidly neutralizes
gastric acid and may provide faster symptomatic relief
independent of accelerated esomeprazole effect. This IR
esomeprazole formulation with sodium bicarbonate may
have an advantage of relieving symptoms rapidly and
efﬁciently in acid-related disorders.
Maintenance of intragastric pH above 4.0 has been
considered a reliable surrogate marker for relieving the
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symptoms of acid-related disorders and healing GERD.21
The severity and frequency of heartburn or pain in GERD
correlate with the duration of esophageal exposure to the
reﬂuxate with pH <4.0.22 However, the value of intragas-
tric pH <4.0 is considered the same whether the pH is 3.9
or 1.0 for the same period of time, which is a major
limitation in the identiﬁcation of actual intragastric
acidity.21 In order to overcome this, the integrated
intragastric acidity has been used as a more precise
method to assess the intragastric acid control.21 In this
study, we measured both the mean percentage time for
the intragastric pH >4.0 and integrated intragastric acid-
ity for a 24-hr interval to evaluate the antacid effect.
After treatment with IR-ESO, the mean percentage
times observed with gastric pH >4.0 were about 56.8–
69.9%, and percentage decrease in the 24-hr integrated
intragastric acidity from baseline was about 64.4–80.4%.
Both these parameters were similar to those in the group
with administration of enteric-coated esomeprazole, sug-
gesting that IR-ESO has a similar potency as enteric-
coated esomeprazole to treat GERD.12
Zegerid approved by the FDA is similar to IR-ESO
formulation of this study, since it contained sodium bicar-
bonate and immediate-release formulation of PPI.6 In a
previous study to compare Zegerid and enteric-coated
omeprazole, the Tmax for Zegerid was much lower than
that of enteric-coated omeprazole (0.50 vs 1.38 hrs).20
Comparative symptom relief in patients with GERD
showed that patients who consumed Zegerid demonstrated
a remarkable and rapid symptom relief within 30 mins,
while patients with treated with enteric-coated omeprazole
did not show the same effect.20 These observations suggest
that absorption of IR formulation PPI occurs rapidly due to
the buffer effect of sodium bicarbonate and treatment also
works rapidly because of the antacid effect of sodium
bicarbonate in addition to accelerated effects of rapidly
absorbed PPI.20 Based on these results, IR-ESO, which
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Figure 3 Median intragastric pH within 2 hrs with esomeprazole 20 mg/sodium bicarbonate 800 mg (test) or esomeprazole 20 mg (reference) at baseline, (A) after a single
administration on day 1 and (B) after multiple administrations on day 7.
Notes: Reference, esomeprazole 20 mg once daily for 7 days. Test, esomeprazole 20 mg/sodium bicarbonate 800 mg once daily for 7 days.
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showed shorter Tmax than enteric-coated esomeprazole, is
expected to cause faster symptomatic relief of GERD
because of rapid absorption and increased antacid effects.
The Cmax values for IR-ESO were about 1.4- to 1.5-
fold higher than those of enteric-coated esomeprazole;
however, the AUC of esomeprazole was similar between
the two groups. As observed in a previous study, wherein
the AUC of esomeprazole predicts the efﬁcacy of acid
inhibition more precisely, the acid inhibitory effect of IR-
ESO was comparable to that of enteric-coated esomepra-
zole, similar to the results of AUC.23 There are safety
concerns of IR-ESO resulting from higher Cmax values
than those of enteric-coated esomeprazole. However, the
frequency or severity of ADR was similar between the two
groups, and the ADRs were not clinically signiﬁcant. On
the basis of these results, IR-ESO is considered to be safe
irrespective of higher plasma peak concentration.
Despite these ﬁndings, this study has several limita-
tions. First, it included only healthy adult male sub-
jects, and the results cannot be generalized for patients
with GERD. However, the main objective of this study
was to compare the PK/PD of esomeprazole between
the two drugs, and it is important to control any factors
that may affect the PK/PD such as concomitant medi-
cation, disease status, lifestyles, and so on. Therefore,
it was reasonable to conduct the study only in healthy
subjects for controlling these factors strictly. In the
future, further studies in patients with acid-related dis-
orders might be needed to evaluate the acid inhibitory
effect and clinical efﬁcacy by observation of symptom
control or rate of healing of IR-ESO. Second, the
serum gastrin concentrations were not analyzed in this
study. Since the serum gastrin level can be elevated
depending on the degree of acid inhibition, there is a
good correlation between serum gastrin and gastric
acid suppression.23 However, in this study, 24-hr pH
monitoring and 24-hr integrated intragastric acidity
monitoring were considered sufﬁcient to evaluate the
degree of acid inhibition.
Conclusion
Results from the present study suggested that IR-ESO
showed similar PK/PD proﬁles as enteric-coated esome-
prazole in healthy male adults. Furthermore, this study
demonstrates that IR-ESO exhibited a faster onset com-
pared with enteric-coated esomeprazole, such that median
Tmax and the initial time to reach pH >4 were shorter.
During the course of the study, IR-ESO and enteric-coated
esomeprazole were well tolerated and safe. All ADRs
were mild and recovered without any complications. As
the study population was limited to healthy male Korean
population, further studies are required to evaluate whether
there is a difference of PK/PD proﬁles of IR-ESO between
both gender, a wider age range and patient with acid-
related disorders.
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Table 3 Summary of 24-hr integrated gastric acidity and comparison of percent change from baseline in integrated gastric acidity over
a 24-hr interval after single and multiple administrations
R (n=37) T (n=37) GeoLSM GMR (90% CI)
R T T/R
Baseline (mmol·hr/L) 326.83±685.43 247.81±208.29
Single (mmol·hr/L) 108.59±179.32 141.10±371.38
Multiple (mmol·hr/L) 45.43±37.92 47.56±36.93
Single % change (%) 64.4±21.4 47.2±122.5 64.0 64.5 1.01 (0.93–1.09)
Multiple % change (%) 80.4±16.3 79.2±14.9 78.3 78.0 1.00 (0.95–1.04)
Notes: Data are presented as mean±SD. R, esomeprazole 20 mg; T, esomeprazole 20 mg/sodium bicarbonate 800 mg. Single % change (%), percentage decrease from
baseline in integrated acidity for a 24 hr interval after single administration; multiple % change (%), percentage decrease from baseline in integrated acidity for a 24 hr interval
after multiple administration.
Abbreviations: SD, standard deviation; GeoLSM, geometric least squares mean ratio; GMR, geometric least squares mean ratio; CI, conﬁdence interval.
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